Severe hypoglycaemia, cardiovascular outcomes and death: Experience from the 'Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results' (LEADER) trial

被引：0
|
作者：
Bain, S. [1 ]
Zinman, B. [2 ]
Marso, S. P. [3 ]
Christiansen, E. [4 ]
Calanna, S. [4 ]
Rasmussen, S. [4 ]
Buse, J. B. [5 ]
机构：
[1] Univ Swansea, Sch Med, Swansea, W Glam, Wales
[2] Univ Toronto, Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada
[3] Res Med Ctr, Kansas City, MO USA
[4] Novo Nordisk AS, Soborg, Denmark
[5] Univ N Carolina, Sch Med, Chapel Hill, NC USA
来源：
DIABETIC MEDICINE | 2018年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A17
引用
收藏
页码：11 / 11
页数：1
相关论文
共 50 条
  • [1] Follow the LEADER—Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Trial
    Sanjay Kalra
    Diabetes Therapy, 2016, 7 : 601 - 609
  • [2] Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial
    Marso, Steven P.
    Poulter, Neil R.
    Nissen, Steven E.
    Nauck, Michael A.
    Zinman, Bernard
    Daniels, Gilbert H.
    Pocock, Stuart
    Steinberg, William M.
    Bergenstal, Richard M.
    Mann, Johannes F. E.
    Ravn, Lasse Steen
    Frandsen, Kirstine Brown
    Moses, Alan C.
    Buse, John B.
    AMERICAN HEART JOURNAL, 2013, 166 (05) : 823 - +
  • [3] Liraglutide and renal outcomes in Type 2 diabetes: results of the 'Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results' (LEADER) trial
    Poulter, N.
    Mann, J. F. E.
    Brown-Frandsen, K.
    Daniels, G. H.
    Kristensen, P.
    Nauck, M. A.
    Nissen, S. E.
    Pocock, S.
    Buse, J. B.
    Petrie, J.
    DIABETIC MEDICINE, 2017, 34 : 23 - 24
  • [4] Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER)
    Meier, J. J.
    Nitschmann, S.
    INTERNIST, 2017, 58 (03): : 303 - 305
  • [5] Liraglutide effect and action in diabetes: evaluation of cardiovascular outcome and results (LEADER) trial design and methods
    Marso, S. P.
    Poulter, N. R.
    Nissen, S. E.
    Nauck, M. A.
    Zinman, B.
    Pocock, S.
    Bergenstal, R. M.
    Mann, J. F. E.
    Ravn, L. S.
    Moses, A. C.
    Buse, J.
    DIABETOLOGIA, 2013, 56 : S37 - S37
  • [6] Follow the LEADER-Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Trial
    Kalra, Sanjay
    DIABETES THERAPY, 2016, 7 (04) : 601 - 609
  • [7] Severe hypoglycaemia, cardiovascular outcomes and death: the LEADER experience
    Zinman, B.
    Marso, S. P.
    Christiansen, E.
    Calanna, S.
    Rasmussen, S.
    Buse, J. B.
    DIABETOLOGIA, 2017, 60 : S74 - S75
  • [8] Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER™) Trial: Rationale and Study Design
    Bergenstal, Richard
    Daniels, Gilbert
    Mann, Johannes
    Nissen, Steven
    Pocock, Stuart
    Zinman, Bernard
    Buse, John
    Moses, Alan
    Zychma, Marcin
    Marso, Steven
    DIABETES, 2011, 60 : A612 - A613
  • [9] LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations
    Daniels, G. H.
    Hegedus, L.
    Marso, S. P.
    Nauck, M. A.
    Zinman, B.
    Bergenstal, R. M.
    Mann, J. F. E.
    Karsbol, J. Derving
    Moses, A. C.
    Buse, J. B.
    Tuttle, M.
    DIABETES OBESITY & METABOLISM, 2015, 17 (05): : 477 - 486
  • [10] Severe Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience
    Zinman, Bernard
    Marso, Steven P.
    Christiansen, Erik
    Calanna, Salvatore
    Rasmussen, Soren
    Buse, John B.
    DIABETES, 2017, 66 : A95 - A95
12345